Every patient and family you see is inescapably impacted by weight stigma or fat shaming and the damage from this bias can lethal.

On 9/6/22 the FDA approved Stanford’s SAINT Neuromodulation, an accelerated version of TMS that has raised hopes with unusually high remission rates.

Antidepressants in mania and stimulants in psychotic disorders get called out in our first psychopharm commandment. 

The expanding population of older adults has created a need for all clinicians to participate in their care. Interviewing techniques require adaptation in older adults, such as accounting for hearing or vision impairment and speaking slowly and clearly. This podcast will cover additional factors to consider when evaluating older patients.

Silexan, an extract from Lavender with pharmaceutical properties, is one of only two treatments with a large effect size in generalized anxiety disorder. We rank all the treatments by strength and look to see if any of them can work when the SSRIs do not.

Richard Brown discusses symptoms that often get in the way of full recovery in ADHD, including dyslexia, and problems with working memory, processing speed, and executive function. 

Nine years after DSM-5, Avoidant Restrictive Food Intake Disorder (ARFID) is still settling into clinical practice. Dr. Jennifer Thomas helps sort out the differential diagnosis between ARFID, anorexia, and other conditions and plan treatment in the context of comorbid conditions, such as anxiety disorders and Autism Spectrum Disorder.

Topiramate can cause psychosis, or treat psychosis; worsen cognition, or improve it; cause depression or… You get the point. A look at the paradoxical world of psychopharmacology.

Second-generation antipsychotics routinely breach the FDA’s level of concern of >7% body weight gain. This article examines the efficacy and safety of using off-label medications, such as metformin, to manage this side effect.

Carl Salzman removes the stigma from the much maligned benzo, reminding us of when they are essential to treatment and when they cause harm. Dr. Salzman is the past chairman of the American Psychiatric Association’s Benzodiazepine Task Force.